Identification and functional characterization of a novel PAX8 mutation (p.His39Pro) causing familial thyroid hypoplasia

Megumi Iwahashi-Odano1*, Yasuko Fujisawa2*, Tsutomu Ogata2, Shinichi Nakashima2, Mayumi Muramatsu2, and Satoshi Narumi1

1Department of Molecular Endocrinology, National Research Institute for Child Health and Development, Tokyo, Japan
2Department of Pediatrics, Hamamatsu University School of Medicine, Hamamatsu, Japan

Abstract. Mutations in PAX8, the gene for a thyroid-specific transcription factor, causes congenital hypothyroidism (CH) with autosomal dominant inheritance. All previously detected PAX8 mutations except one are located in the DNA-binding paired domain. The proband, a 1-yr-old boy, was diagnosed with CH in the frame of newborn screening. He had high serum TSH level (180 mU/L) and low serum free T4 level (0.4 ng/dL). Ultrasonography revealed that the proband had thyroid hypoplasia. Importantly, he had a family history of CH, i.e., his mother also had CH and hypoplasia. Next generation sequencing-based mutation screening revealed a novel heterozygous PAX8 mutation (c.116A>C, p.His39Pro) that was transmitted to the proband from the mother. Expression experiments with HeLa cells confirmed that His39Pro-PAX8 exhibited defective transactivation of the TG promoter–luciferase reporter. In conclusion, we identified and described a novel loss-of-function PAX8 mutation in a family with thyroid hypoplasia. Patients with dominantly inherited CH and no extrathyroidal abnormalities could have PAX8 mutations.

Key words: PAX8, mutation, genetics, congenital hypothyroidism

Introduction

Molecular biology studies have revealed that organogenesis of the thyroid gland is regulated by several tissue-specific transcription factors [i.e., thyroid transcription factors (TTFs)]. Three TTFs, namely, PAX8 (1, 2), NKX2-1 (formerly known as TTF-1) (3, 4), and FOXE1 (formerly known as TTF-2) (5) have been known to play important roles in this process. PAX8 is a member of the PAX gene family. Transcription factors of the PAX family are characterized by the presence of a DNA-binding paired domain at their N terminus. PAX8 regulates the transcription of thyroid-specific genes, including thyroglobulin (Tg) and thyroid peroxidase, in cultured cell lines (6). Pax8-knockout mice have thyroid hypoplasia due to defective proliferation and survival of thyroid precursor cells (7). In humans, heterozygous PAX8 mutations cause congenital hypothyroidism (CH) with autosomal dominant inheritance (8). The prevalence of PAX8 mutations is 2.0% among Japanese patients with CH, 3.5% among German patients with CH, and 1.7% among Chinese patients with CH (9–12).

To date, CH has been described in 77 patients belonging to 30 families (9, 10, 13–29). Clinical phenotypes of mutation carriers are variable, ranging from overt CH with severe thyroid hypoplasia to subclinical CH with a normal-sized thyroid. Of the previously reported and experimentally verified PAX8 mutations, 95% have been identified in the paired domain. In the present study, we aimed to identify and functionally characterize a novel CH-associated PAX8 mutation located in the paired domain.

Patients and Methods

Patient report

The proband, a 1-yr-old boy, was born at 40 wk of gestation after an uneventful term pregnancy. The birth weight and birth length of the proband were 2,772 g and 48 cm, respectively. The proband was brought to medical attention due to high blood spot TSH level
(78.1 mU/L; cutoff level, 9.5) at newborn screening for CH. His mother also suffered from CH and has been undergoing levothyroxine (L-T4) replacement therapy (Fig 1A). At 10 days of age, the proband had high serum TSH level (180 mU/L; reference 1.7–9.1), low serum free T4 level (0.8 ng/dL; reference 0.9–2.3), and normal serum Tg level (32.8 ng/mL; reference 3.8–56) (Table 1). However, he did not have any CH-related symptoms, including constipation, jaundice, and poor weight gain; and his kidney ultrasound results were normal. He was diagnosed with primary CH, and L-T4 replacement therapy (10 µg/kg/d) was started since then. When the proband was 1.7 yr old, his stature was short (74.5 cm; –2.5 SD), although his weight was normal (8.9 kg; –1.6 SD). He achieved developmental milestones normally, i.e., walked independently, spoke a few words, and followed simple directions at 1.7 yr of age. At the age of 1.9 yr, ultrasonography revealed normoechoic hypoplastic thyroid gland in the proband (–3.7 SD; Fig. 1B). At the last clinical visit (age, 1.9 yr), the proband was doing well with 4.5 µg/kg/d of L-T4 treatment.

The mother of the proband, aged 32 yr, was diagnosed with CH within the frame of newborn screening for CH, and underwent L-T4 replacement therapy since then. At the last clinical visit, she was doing well with 2.5 µg/kg/d of L-T4 treatment. She reportedly had thyroid hypoplasia, which was detected by ultrasonography in the neonatal period; however, the ultrasound image is unavailable.

**Mutation detection**

This study was approved by the ethics committee of National Center for Child Health and Development.

---

**Fig. 1.** Identification of a novel heterozygous PAX8 mutation. (A) Pedigree of the mutation-carrying patients. Black symbols indicate individuals with congenital hypothyroidism. NE, not evaluated. (B) Ultrasonography of the mutation carrier showed normoechoic hypoplastic thyroid gland. The widths of the left and right lobes were 7.1 mm and 4.5 mm, respectively. Scale bar corresponds to 5 mm. (C) Electropherogram of the mutation carrier revealed the presence of a heterozygous mutation (c.116A>C, p.His39Pro). (D) Single-letter amino acid ClustalW alignments of residues surrounding His39. The mutated residue, which is conserved among vertebrate species, is shown in red. (E) A schematic diagram showing the secondary structure of the paired domain of PAX8. The two β-sheets and six α-helices are represented as boxes. The location of p.His39Pro is indicated with a red arrow. Black bars indicate the locations of previously reported missense PAX8 mutations.

**Table 1.** Clinical summary of PAX8-mutation carriers

| Variable                      | Proband | Proband’s mother |
|-------------------------------|---------|------------------|
| Age (yr)                      | 1       | 32               |
| Sex                           | M       | F                |
| Age at diagnosis (yr)         | 0.1     | 0.1              |
| Thyroid function              |         |                  |
| Age at evaluation (yr)        | 0.1     | NA               |
| Serum TSH (mU/L)              | 180.1   | NA               |
| Serum free T4 (ng/dL)         | 0.8     | NA               |
| Serum Tg (ng/mL)              | 32.8    | NA               |
| Thyroid ultrasonography       | Hypoplasia | Hypoplasia     |

NA: not available.

---
Written informed consent for molecular analysis was obtained from the parents of the proband. Eleven known genes associated with primary CH (DUOX2, DUOX2A, FOXE1, IYD, NKX2-1, PAX8, SLC5A5, SLC26A4, TG, TPO, and TSHR) were analyzed using MiSeq next-generation sequencer (Illumina Inc., San Diego, CA, USA) as previously described (30). The variants in next generation sequencing were confirmed by PCR-based Sanger sequencing. The detected mutations were referred for 4.7KJPN (https://jmorp.megabank.tohoku.ac.jp/202001/variants; Japanese genetic variant database), 1000 Genomes Project (http://www.1000genomes.org/), and genome aggregation (https://gnomad.broadinstitute.org/) databases.

**Functional characterization of His39Pro-PAX8**

Vectors expressing untagged human PAX8 (PAX8A; NM_0034466) or human NKX2-1 cDNA (NM_004387), and luciferase reporter vector encoding the promoter sequence of the human TG gene (TG-luc) were constructed as described previously (9). An expression vector encoding N-terminal 3xFLAG-tagged human PAX8 was constructed by introducing the 3xFLAG sequence using Gibson assembly technique (NEBuilder HiFi DNA Assembly Master Mix; New England Biolabs, Ipswich, MA, USA). The PAX8 mutation His39Pro was introduced into these vectors using PrimeSTAR Mutagenesis Basal Kit (TaKaRa Bio Inc, Shiga, Japan) according to the manufacturer’s protocol. HEla cells were maintained in DMEM supplemented with 10% FBS, 100 U/mL penicillin, and 100 μg/mL streptomycin. Transient transfection was performed with Lipofectamine 3000 reagent (Thermo Fisher Scientific, Waltham, MA, USA) following to the manufacturer’s protocol. For western blotting, cells transfected with 3xFLAG-tagged PAX8 construct (WT or mutant) or empty vector were harvested at 48 h post transfection, and whole cell lysates were obtained by treating the cells with 1% Triton X-100/Tris buffered saline (TBS) supplemented with protease inhibitor cocktail. The lysates were resolved using 10% SDS–PAGE, and western blotting was performed using monoclonal anti-FLAG M2 antibody (Sigma-Aldrich, St. Louis, MD, USA) as the primary antibody and horseradish peroxidase-conjugated goat anti-mouse IgG antibody (Sigma-Aldrich) as the secondary antibody. For visualization of subcellular localization, cells were fixed in 4% formaldehyde/PBS at room temperature for 10 min. Blocking and plasma membrane permeabilization were performed by incubating the cells with 5% bovine serum albumin (BSA) in TBS supplemented with 0.1% Triton X-100 at room temperature for 1 h. Immunofluorescence was performed using anti-FLAG M2 antibody (Sigma-Aldrich) as the primary antibody and Alexa Fluor 555-conjugated goat anti-mouse IgG antibody (Thermo Fisher Scientific) as the secondary antibody. For transactivation assays, cells were co-transfected with 90 ng of TG-luc and 10 ng of PAX8 expression vector (WT or mutant) with or without 1 ng of NKX2-1 expression vector. Luciferase activity was measured 48 h post transfection using ONE-Glo Luciferase Assay System (Promega, Madison, WI, USA) according to the manufacturer’s instructions. Data are representative of four independent experiments with similar results.

**Results**

**Mutation detection**

To clarify the molecular basis of familial thyroid hypoplasia of the pedigree, we conducted next generation sequencing-based mutation screening in the proband. As a result, we identified a novel heterozygous PAX8 mutation (c.116A>C, p.His39Pro) (Fig. 1C). No mutation was found in any of the other sequenced genes. The His39 residue is conserved among vertebrate species with thyroid gland (Fig. 1D). The paired domain consists of two β-sheets (61 and 82) and six α-helices (a1 to o6). His39 is located in the first α-helix of the paired domain (Fig. 1E). Family study revealed that the mutation was transmitted from the mother, who was also affected by CH, to the proband (Fig. 1A).

**In vitro functional analyses**

To verify the pathogenicity of the identified PAX8 mutation (His39Pro), we conducted a series of transient expression experiments in HeLa cells, a cell line derived from cervical cancer cells. Western blotting of 3xFLAG-tagged PAX8 proteins showed that the protein expression level of His39Pro-PAX8 was comparable with that of WT-PAX8 (Fig. 2A). Visualization of subcellular localization of the 3xFLAG-tagged PAX8 protein revealed that His39Pro-PAX8 was localized in the nucleus (Fig. 2B). The transactivation capacity of His39Pro-PAX8 was tested using TG-luc. To evaluate the interaction between PAX8 and its transcriptional partner NKX2-1, different co-transfection patterns were tested: His39Pro-PAX8 only or both WT- and His39Pro-PAX8, each with or without co-expressed NKX2-1. In the absence of NKX2-1, His39Pro-PAX8 showed negligible transactivation of TG-luc (Fig. 2C, red bar). Co-transfection of WT-PAX8 (5 ng) and His39Pro-PAX8 (5 ng) showed no dominant negative effect as compared to transfection with WT only (5 ng) (Fig. 2C, red and grid bars). In the presence of NKX2-1, the transactivating capacity of His39Pro-PAX8 (10 ng) was comparable with that of WT (10 ng) (81 ± 12% activity relative to WT-PAX8) (Fig. 2D, red bar). Moreover, when WT- and His39Pro-PAX8 were co-transfected (WT 5 ng; mutant 5 ng), the transactivation level of TG-luc was significantly lower than that obtained with 10 ng of WT but was comparable to that obtained with 5 ng of WT (Fig. 2D, red and grid bars).

**Discussion**

In the present study, we identified a novel PAX8 mutation (p.His39Pro) causing familial thyroid
hypoplasia. To date, 30 families of CH caused by PAX8 mutations have been described (9, 10, 13–29). For 25 families, genetic analyses for family members were performed, showing parent-to-offspring transmission in 21 families (9, 10, 13–20, 22–25, 27, 28) and de novo occurrence of the mutation in five (13, 23, 26). Among the 21 families that displayed parent-to-offspring mutation transmission, 19 exhibited familial hypothyroidism, while two showed incomplete penetrance. These findings suggest the importance of family history of CH to suspect PAX8 mutations on clinical grounds.

The p.His39Pro mutation exhibited negligible transactivation of TG-luc in the absence of NKX2-1, but showed significant transactivation in the presence of NKX2-1. This transcriptional “rescue” has been repeatedly reported in missense PAX8 mutations located in the paired domain (9, 20, 23). Grasberger et al. pointed out that formation of PAX8–NKX2-1 complex in the TG promoter would be the molecular basis for the phenomenon (18). In this model, the PAX8 protein, the NKX2-1 protein, and the TG promoter bind each other, therefore, defective binding between PAX8 and the TG promoter can be rescued by NKX2-1 that bridges PAX8 and the TG promoter. In this study, we demonstrated that the rescue by NKX2-1 was abolished by co-transfection of WT- and His39Pro-PAX8. This observation implies that NKX2-1 binds more preferentially to WT-PAX8 than His39Pro-PAX8, therefore, His39Pro-PAX8 was no longer rescued by NKX2-1. In our expression experiments, the condition that best recapitulated the thyroid status of the patient was co-expression of WT- and His39Pro-PAX8 in the presence of NKX2-1. However, this condition resulted in approximately 50% loss of transactivation capacity. Considering that CH is caused by haploinsufficiency of PAX8, we assume that this 50% reduction is sufficient to cause CH (23).

In our previous study, we performed functional analysis of His39Ala mutation, and found that it retains residual transactivation capacity (43 ± 3%) (31). The difference in the degrees of loss of function between His39Pro and His39Ala mutations can be explained by the nature of the substitutions: His to Ala mutation affects the side chain only, while His to Pro mutation affects both the main chain and the side chain. A similar discordance has also been observed in Gln40Pro and Gln40Ala mutations (31).
Conclusions

We report clinical and molecular findings of a novel PAX8 mutation (p.His39Pro) that caused CH in the proband and the mother. In dominantly-inherited thyroid hypoplasia patients with no extrathyroidal abnormalities, the PAX8 defect should be suspected.

Conflict of interest: The authors declare no conflicts of interest.

Acknowledgements

This study was supported by JSPS KAKENHI (19K22607) to SN.

References

1. Plachov D, Chowdhury K, Walther C, Simon D, Guenet JL, Gruss P. Pax8, a murine paired box gene expressed in the developing excretory system and thyroid gland. Development 1990;110: 643–51. [Medline] [CrossRef]
2. Zannini M, Francis-Lang H, Plachov D, Di Lauro R. Pax-8, a paired domain-containing protein, binds to a sequence overlapping the recognition site of a homeodomain and activates transcription from two thyroid-specific promoters. Mol Cell Biol 1992;12: 4230–41. [Medline] [CrossRef]
3. Guazzi S, Price M, De Felice M, Dumante G, Mattei MG, Di Lauro R. Thyroid nuclear factor 1 (TTF-1) contains a homeodomain and displays a novel DNA binding specificity. EMBO J 1990;9: 3631–9. [Medline] [CrossRef]
4. Lazzaro D, Price M, de Felice M, Di Lauro R. The transcription factor TTF-1 is expressed at the onset of thyroid and lung morphogenesis and in restricted regions of the foetal brain. Development 1991;113: 1093–104. [Medline] [CrossRef]
5. Zannini M, Avantaggiato V, Biffiali E, Amone MI, Sato K, Pischetola M, et al. TTF-2, a new forkhead protein, shows a temporal expression in the developing thyroid which is consistent with a role in controlling the onset of differentiation. EMBO J 1997;16: 3185–97. [Medline] [CrossRef]
6. Di Palma T, Nitsch R, Mascia A, Nitsch L, Di Lauro R, Zannini M. The paired domain-containing factor Pax8 and the homeodomain-containing factor TTF-1 directly interact and synergistically activate transcription. J Biol Chem 2003;278: 3395–402. [Medline] [CrossRef]
7. Mansour A, Chowdhury K, Gruss P. Follicular cells of the thyroid gland require Pax8 gene function. Nat Genet 1998;19: 87–90. [Medline] [CrossRef]
8. Koznik Z, Kurzbauer R, Dörfler P, Busslinger M. Alternative splicing of Pax-8 gene transcripts is developmentally regulated and generates isoforms with different transactivation properties. Mol Cell Biol 1993;13: 6024–35. [Medline] [CrossRef]
9. Narumi S, Muroya K, Asakura Y, Adachi M, Hasegawa T. Transcription factor mutations and congenital hypothyroidism: systematic genetic screening of a population-based cohort of Japanese patients. J Clin Endocrinol Metab 2010;95: 1981–5. [Medline] [CrossRef]
10. Ramos HE, Carré A, Chevrier L, Szimai G, Tron E, Cerqueira TL, et al. Extreme phenotypic variability of thyroid dysgenesis in six new cases of congenital hypothyroidism due to PAX8 gene loss-of-function mutations. Eur J Endocrinol 2014;171: 499–507. [Medline] [CrossRef]
11. Liu SG, Zhang SS, Zhang LQ, Li WJ, Zhang AQ, Lu KN, et al. Screening of PAX8 mutations in Chinese patients with congenital hypothyroidism. J Endocrinol Invest 2012;35: 889–92. [Medline] [CrossRef]
12. Lanzerath K, Bettendorf M, Haag C, Kneppo C, Schulze E, Grulich-Henn J. Screening for Pax8 mutations in patients with congenital hypothyroidism in South-West Germany. Horm Res 2006;66: 96–100. [Medline] [CrossRef]
13. Macchia PE, Lapi P, Krude H, Pirro MT, Missiro C, Chiovato L, et al. PAX8 mutations associated with congenital hypothyroidism caused by thyroid dysgenesis. Nat Genet 1998;19: 83–6. [Medline] [CrossRef]
14. Congdon T, Nguyen LQ, Nogueira CR, Habiby RL, Medeiros-Neto G, Kopp P. A novel mutation (Q40P) in PAX8 associated with congenital hypothyroidism and thyroid hypoplasia: evidence for phenotypic variability in mother and child. J Clin Endocrinol Metab 2001;86: 3962–7. [Medline] [CrossRef]
15. Vlaim C, Rydlewska C, Duprez L, Heinrichs C, Abramowicz M, Malvaux P, et al. Autosomal dominant transmission of congenital thyroid hypoplasia due to loss-of-function mutation of PAX8. J Clin Endocrinol Metab 2001;86: 234–8. [Medline] [CrossRef]
16. de Sanctis L, Corrias A, Romagnolo D, Di Palma T, Biava A, Borgarello G, et al. Familial PAX8 small deletion (c.989-992delACCC) associated with extreme phenotype variability. J Clin Endocrinol Metab 2004;89: 5669–74. [Medline] [CrossRef]
17. Meuse L, Gilbert B, Rydlewska C, Parma J, Roussie AL, Abramowicz M, et al. Characterization of a novel loss of function mutation of PAX8 in a familial case of congenital hypothyroidism with in-place, normal-sized thyroid. J Clin Endocrinol Metab 2004;89: 4285–91. [Medline] [CrossRef]
18. Grasberger H, Ringkananont U, Lefrancois P, Abramowicz M, Vassart G, Refetoff S. Thyroid transcription factor 1 rescues PAX8/p300 synergism impaired by a natural PAX8 paired domain mutation with dominant negative activity. Mol Endocrinol 2005;19: 1779–91. [Medline] [CrossRef]
19. Al Taji E, Biebermann H, Limanová Z, Hníková O, Zikmund J, Dame C, et al. Screening for mutations in transcription factors in a Czech cohort of 170 patients with congenital and early-onset hypothyroidism: identification of a novel PAX8 mutation in dominantly inherited early-onset non-autoimmune hypothyroidism. Eur J Endocrinol 2007;156: 521–9. [Medline] [CrossRef]
20. Di Palma T, Zampella E, Filipponi MG, Macchia PE, Ris-Stalpers C, de Vroede M, et al. Characterization of a novel
loss-of-function mutation of PAX8 associated with congenital hypothyroidism. Clin Endocrinol (Oxf) 2010;73: 808–14. [Medline] [CrossRef]

21. Jo W, Ishizu K, Fujieda K, Tajima T. Congenital hypothyroidism caused by a PAX8 gene mutation manifested as sodium/iodide symporter gene defect. J Thyroid Res 2010;2010: 619013. [Medline] [CrossRef]

22. Narumi S, Yoshida A, Muroya K, Asakura Y, Adachi M, Fukuzawa R, et al. PAX8 mutation disturbing thyroid follicular growth: a case report. J Clin Endocrinol Metab 2011;96: E2039–44. [Medline] [CrossRef]

23. Narumi S, Araki S, Hori N, Muroya K, Yamamoto Y, Asakura Y, et al. Functional characterization of four novel PAX8 mutations causing congenital hypothyroidism: new evidence for haploinsufficiency as a disease mechanism. Eur J Endocrinol 2012;167: 625–32. [Medline] [CrossRef]

24. Carvalho A, Hermanns P, Rodrigues AL, Sousa I, Anselmo J, Bikker H, et al. A new PAX8 mutation causing congenital hypothyroidism in three generations of a family is associated with abnormalities in the urogenital tract. Thyroid 2013;23: 1074–8. [Medline] [CrossRef]

25. Hermanns P, Grasberger H, Cohen R, Freiberg C, Dörr HG, Refetoff S, et al. Two cases of thyroid dysgenesis caused by different novel PAX8 mutations in the DNA-binding region: in vitro studies reveal different pathogenic mechanisms. Thyroid 2013;23: 791–6. [Medline] [CrossRef]

26. Zou H, Chai J, Liu S, Zang H, Yu X, Tian L, et al. A de novo PAX8 mutation in a Chinese child with congenital thyroid dysgenesis. Int J Clin Exp Pathol 2015;8: 11434–9. [Medline]

27. Löf C, Patyra K, Kuulasmaa T, Vangipurapu J, Undeutsch H, Jaeschke H, et al. Detection of novel gene variants associated with congenital hypothyroidism in a Finnish patient cohort. Thyroid 2016;26: 1215–24. [Medline] [CrossRef]

28. Srichomkwun P, Admoni O, Refetoff S, de Vries L. A novel mutation (S54C) of the PAX8 gene in a family with congenital hypothyroidism and a high proportion of affected individuals. Horm Res Paediatr 2016;86: 137–42. [Medline] [CrossRef]

29. Qian F, Li GY, Wu XJ, Jia Q, Lyu GT, Wang ML, et al. Novel non-synonymous mutations of PAX8 in a cohort of Chinese with congenital hypothyroidism. Chin Med J (Engl) 2019;132: 1322–7. [Medline] [CrossRef]

30. Yoshizawa-Ogasawara A, Ogikubo S, Satoh M, Narumi S, Hasegawa T. Congenital hypothyroidism caused by a novel mutation of the dual oxidase 2 (DUOX2) gene. J Pediatr Endocrinol Metab 2013;26:1-2:45-52.

31. Iwahashi M, Narumi S. Systematic alanine scanning of PAX8 paired domain reveals functional importance of the N-subdomain. J Mol Endocrinol 2019;62: 129–35. [Medline] [CrossRef]